ArticleFrontiers in bioengineering and biotechnology2026
pH-responsive Zn
Article in Frontiers in bioengineering and biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Osteoarthritis (OA) is a degenerative joint disease characterized by progressive degradation of the articular cartilage matrix, pain-related functional impairment, and a paucity of effective disease-modifying therapies. Curculigoside (Cur), a bioactive compound isolated from Curculigo orchioides, possesses anti-inflammatory and tissue-protective properties; however, its direct intra-articular application is hampered by insufficient local retention and limited sustained action. Methods: We developed a Zn Results: PGG-Zn@Cur exhibited excellent cytocompatibility and restored cartilage matrix metabolic homeostasis in IL-1β-stimulated chondrocytes, as evidenced by increased COL2A1 and ACAN expression and reduced MMP13, ADAMTS5, and iNOS levels. Transcriptomic analysis implicated PI3K-AKT signaling and apoptosis-related pathways in the chondroprotective effects mediated by PGG-Zn@Cur. Mechanistically, PGG-Zn@Cur suppressed PI3K-AKT pathway hyperactivation, downregulated Cleaved Caspase-3 and Bax expression, attenuated chondrocyte apoptosis, and alleviated cartilage degeneration. Discussion: These findings establish PGG-Zn@Cur as a microenvironment-responsive intra-articular platform that maintains cartilage matrix homeostasis and alleviates PI3K-AKT-associated apoptosis-related responses, offering a promising strategy for disease-modifying OA therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.